Guide

How a claim keeps its identity across revisions

A claim is rarely deleted. It is reworded, moved, qualified, broadened, narrowed, given a new citation, and occasionally put back after being taken out. A history is only as good as its ability to say, at each of those steps, that this is still the same claim.

What counts as the same claim

The system holds one identity across paraphrase, wording change, broadening, narrowing, qualification, relocation to another section or document, removal, reintroduction, and citation replacement. A sentence that says “reduces” where it used to say “may reduce” is the same claim with a qualifier gone. A sentence that now names a different population is a different claim, and the history says so rather than quietly carrying the old identity forward.

Why it matters

A public source changes for many reasons: new evidence, delayed editor attention, imported regulator language, citation cleanup, editorial judgement, routine maintenance. A diff that cannot hold identity reports all of them as movement. Held identity is what lets each change be labelled for what it was — and “evidence strengthened” is a label the system applies only when the evidence did.

The inspector

The inspector replays one claim’s wording across clinical, guideline and payer surfaces so a reader can see which revisions changed the proposition and which were housekeeping. Every step names its source surface; nothing here is a judgement about the claim itself.

Trajectory Diff Engine

Multi-Surface Qualifier & Policy Diff Inspector

Reconstruct how assertions shed qualifiers, attach clinical citations, and converge into institutional policy across public revisions.

Trial Publication Rung 1 · Emergence Phase Ib Clinical Readout · 2021-03

Ledger:

Extracted Proposition Diff

Monoclonal antibody demonstrates robust amyloid plaque reduction in early analysis; biomarker clearance is observed without confirmed downstream clinical slowing or cognitive protection.

Institutional State Initial trial observation shows biomarker clearance without proven clinical slowing.

Language Drift Heavy qualifiers present ('preliminary', 'unconfirmed')

Pivotal Trial Cohort Rung 2 · Replication Phase III Primary Endpoint · 2022-09

Ledger:

Extracted Proposition Diff

Monoclonal antibody demonstrates robust amyloid plaque reduction and a 27% reduction in clinical cognitive decline in Phase III cohort (NEJM 2022), without confirmed downstream clinical slowing.

Institutional State Phase III trial attachments remove exploratory hedges as cognitive slowing trends appear.

Language Drift Negative qualifier struck; evidentiary citation attached

Clinical Society Consensus Rung 5 · Guideline Appropriate Use Recommendations · 2023-04

Ledger:

Extracted Proposition Diff

Therapy demonstrates clinical benefit in early-stage disease; appropriate use criteria recommend administration strictly for biomarker-confirmed amyloid pathology with baseline MCI.

Institutional State Societies adopt specific biomarker-confirmed staging criteria directly from trial endpoints.

Language Drift Hedge removed; explicit eligibility boundaries codified

Payer Policy / CMS Rung 7 · Payer Coverage with Evidence Development · 2023-10

Ledger:

Extracted Proposition Diff

National coverage policy reimburses amyloid-targeting therapies under registry participation requirement, aligning coverage to biomarker-positive mild cognitive impairment cohorts.

Institutional State National coverage policy aligns reimbursement restrictions with guideline diagnostic thresholds.

Language Drift Institutional language converges; restriction operationalized

FDA Labeling Rung 6 · Regulatory Initial Glycemic Approval · 2018-05

Ledger:

Extracted Proposition Diff

Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus; not recommended for patients with moderate to severe renal impairment (eGFR < 45).

Institutional State Approved strictly as a glycemic control agent for Type 2 Diabetes; renal use restricted.

Language Drift Narrow reliance scope with eGFR contraindication qualifier

Pivotal Trial Publication Rung 1 · Emergence Renal Outcome Trial Readout · 2020-11

Ledger:

Extracted Proposition Diff

Indicated to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with chronic kidney disease, irrespective of diabetes status or baseline HbA1c.

Institutional State Trial establishes slowing of kidney disease progression independent of baseline glucose levels.

Language Drift Glycemic dependence qualifier dismantled by RWE/trial readout

Clinical Practice Guideline Rung 5 · Guideline ADA & KDIGO Joint Consensus · 2022-03

Ledger:

Extracted Proposition Diff

Joint consensus guidelines upgrade SGLT2 inhibitors to first-line standard-of-care recommendation (Grade A) for patients with chronic kidney disease and eGFR ≥ 20 mL/min.

Institutional State Guidelines elevate drug class to first-line standard of care for CKD with albuminuria.

Language Drift Conditional recommendation upgraded to first-line standard

Payer Coverage LCD Rung 7 · Payer Commercial & Medicare Formularies · 2023-01

Ledger:

Extracted Proposition Diff

Coverage criteria updated to remove mandatory metformin step-therapy failure and grant unrestricted tier-2 coverage for documented CKD with eGFR 20–60.

Institutional State Step therapy barriers through metformin removed across major national commercial plans.

Language Drift Prior authorization hurdle struck across payer tiers

FDA Approval Summary Rung 6 · Regulatory Anti-Obesity Approval · 2021-06

Ledger:

Extracted Proposition Diff

Indicated for chronic weight management in adults with obesity or overweight; effect on cardiovascular morbidity and mortality has not been established in this non-diabetic cohort.

Institutional State Approval restricted to weight management; cardiovascular protection remains unasserted.

Language Drift Weight-loss sole assertion; cardiovascular benefit disclaimed

Cardiovascular Trial Publication Rung 1 · Emergence SELECT Trial Readout · 2023-08

Ledger:

Extracted Proposition Diff

Indicated to reduce the risk of major adverse cardiovascular events (cardiovascular death, nonfatal MI, nonfatal stroke) in adults with established cardiovascular disease and obesity without diabetes (20% relative risk reduction; p < 0.001).

Institutional State Multi-center trial establishes 20% relative risk reduction in major adverse cardiac events.

Language Drift Non-establishment qualifier replaced with quantified relative risk reduction

Regulatory Indication Rung 6 · Regulatory FDA Label Indication Expansion · 2024-03

Ledger:

Extracted Proposition Diff

Label expanded to include prevention of major adverse cardiovascular events in non-diabetic overweight/obese adult populations with established cardiovascular disease.

Institutional State FDA grants new formal indication for secondary cardiovascular prevention.

Language Drift Primary regulatory indication approved

CMS Coverage Memo Rung 7 · Payer Medicare Part D Guidance · 2024-06

Ledger:

Extracted Proposition Diff

CMS guidance clarifies that Part D plans may reimburse anti-obesity medications when prescribed for medically accepted cardiovascular risk reduction indications.

Institutional State CMS issues guidance allowing Part D plans to cover anti-obesity drugs for CV indication.

Language Drift Statutory anti-obesity exclusion bypassed via secondary CV indication